A Phase 2 interventional study of Intravenous digoxin in Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury and Alcohol-Induced Disorders, sponsored by Yale University. Terminated at 1 site in United States. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Yale University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Chemical and Drug Induced Liver Injury with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Chemical and Drug Induced Liver Injury · United States.
Among the 13 studies in Chemical and Drug Induced Liver Injury with a site in United States, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2021, is one of 4 in phase 2, and was the 9th registered.
81 studies on the registry are indexed under Chemical and Drug Induced Liver Injury; 21 are open to participants now.
Browse Chemical and Drug Induced Liver Injury studies →2 of the 13 studies in Chemical and Drug Induced Liver Injury with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 2+
Cedars-Sinai Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Chemical and Drug Induced Liver Injury studies recruiting now, 7 (58%) set no upper age limit and 3 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 21 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 80 across 41 interventional studies indexed under Chemical and Drug Induced Liver Injury.
Median enrollment 30 across the 10 interventional studies, 400 across the 3 observational. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 13 have an industry lead sponsor. The 10 most frequent:
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
Yale University has 1 study filed under Chemical and Drug Induced Liver Injury — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Chemical and Drug Induced Liver Injury with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, single center, open label, randomized controlled trial to explore whether digoxin treatment affects cytokine levels as biomarkers of inflammation in patients with acute alcohol associated hepatitis, digoxin administration and dose adjustment.
The study intervention will be intravenous digoxin (renal-based dosing for maximum of 28 days) versus no digoxin in an open-label 1:1 randomized allocation of patients with severe acute alcohol associated hepatitis.
Severe alcohol associated hepatitis is a condition of acute on chronic immune liver dysfunction that is associated with high mortality, necessitating a search for drugs that may prove safe and efficacious in treating this disease. Pre-clinical studies suggest that digoxin, which is currently used for treating cardiac conditions, is also effective in improving alcohol-associated liver injury. To date, there have been no clinical studies of digoxin use in patients with alcohol associated hepatitis.
The primary objective of this randomized control study of digoxin versus no digoxin in patients with severe alcohol associated hepatitis is to explore whether digoxin treatment affects cytokine levels as biomarkers of inflammation in patients hospitalized with severe alcohol associated hepatitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Diagnosis of alcohol associated hepatitis based on clinical criteria or histologic evidence
Clinical criteria:
Histological evidence of alcohol associated hepatitis*
2. MDF >32 or MELD ≥ 20 to ≤ 35 on Day 0 of the trial
3. Age between 21 and 70 years, inclusive
* In patients with possible alcohol associated hepatitis with confounding factors such as possible ischemic hepatitis, possible DILI, uncertain history of alcohol use, or atypical/abnormal laboratory tests (e.g., AST \< 50 IU/IU/L or > 400 IU/IU/L, AST/ALT ratio \< 1.5), antinuclearantibody > 1:160 or SMA > 1:80, standard of care liver may be performed as per discretion of the primary attending physician to confirm alcohol associated hepatitis and exclude competing etiologies. The decision to perform liver biopsy will be made by the primary team and will occur regardless of the study. As per current SOC, a liver biopsy may be obtained to confirm suspected alcohol-associated hepatitis and to rule out other potential etiologies of liver disease.
If a liver biopsy is performed for clinically indicated reasons, we will store liver tissue that is left over after the portion needed for the primary indication has been identified.
Exclusion Criteria:
7- History of other liver diseases including (positive HBsAg or HBV DNA), hepatitis 8-C (positive ), hepatitis, Wilson disease, genetic hemochromatosis, alpha1-antitrypsin deficiency.
8-Diagnosis of Drug Induced Liver Injury (DILI), or other etiologies seen on liver imaging.
9 - History of infection (positive HIV RNA or on treatment for HIV infection)
10 - Current diagnosis of cancer
11- Renal failure defined by \<30 mL/min
12 - ascites, defined as having more than 4 paracenteses in the preceding 8 weeks despite diuretic therapy
13 - Prior exposure to experimental therapies or other clinical trial in last 3 months
14 - Current acute or chronic pancreatitis
15 - Active gastrointestinal bleeding unless resolved for >48 hours
16 - Experiencing withdrawal seizures or considered at high risk for alcohol withdrawal seizures or delirium tremens
17 - Heart rate less than 60 bpm at screening visit or at baseline
18 - Current diagnosis of atrial fibrillation
19 - Cardiomyopathy
20 - Heart failure
21 - Severe aortic valve disease
22 - Presence of Accessory arterio-ventricular pathway (eg Wolf-Parkinson-White syndrome)
23 - Complete heart block or second degree arterio-ventricular block without pacemaker or implantable cardiac device
24 - Any of the following within the previous 6 months: myocardial infarction, percutaneous intervention, pacemaker/implantable cardiac device implantation, cardiac surgery or stroke
25 - Current use of the following medications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the digoxin arm, the intervention to be administered will be intravenous digoxin dosed by weight and by renal function using an adaption of the established FDA nomogram. Participants randomized to digoxin will receive an intravenous digoxin loading dose administered in 3 doses over 24 hours starting on Day 1. Digoxin levels will be monitored daily throughout the participant's hospital stay, to a maximum of 28 days. Digoxin will be discontinued at the time discharge if before 28 days.
Drug: Intravenous digoxin
In the no digoxin arm, no study drug or placebo will be administered.
Loading dose: the total loading dose of digoxin will be determined using the Loading nomogram. The FDA-recommended total IV digoxin loading dose range is 8 to 12 mcg/kg. The lowest recommended dose of 8 mcg/kg was used in constructing the digoxin Loading nomogram that will be used in this trial. Maintenance dose: the maintenance dose will be started approximately 24 hours after initiation of digoxin loading. The post-loading digoxin trough will be reviewed prior to starting maintenance dosing. Subjects on P-gp inhibitors or spironolactone, will have an additional digoxin level performed 12-hours after any dose adjustment. Once digoxin levels are stable, 24-hour blood draws will be performed.
Also known as: Lanoxin
Change in Biomarkers of Inflammation
Change in IL-6, IL-10 and TNF-alpha levels (pg/ml) at day 3 in participants with acute alcohol associated hepatitis treated with digoxin vs no digoxin.
Time frame: Day 3
Practicality of Daily Digoxin Measurements
Practicality of daily digoxin measurements is recorded at the participant level as the proportion of timepoints where serum digoxin levels are checked within the pre-specified time window. It is summarized and reported as the mean and standard deviation of the proportion of eligible timepoints.
Time frame: From Day 2 to Day 28 or until discharge, whichever sooner
Feasibility of Digoxin Dosing in a Timely Manner.
Feasibility of digoxin dosing is recorded at the participant level as the proportion of eligible timepoints where the scheduled digoxin dose was given. It is summarized and reported as the mean and standard deviation of the proportion of scheduled timepoints.
Time frame: From Day 1 to Day 28 or until discharge, whichever sooner
Feasibility of Digoxin Dose Adjustments in Renal Insufficiency.
Feasibility of digoxin dose adjustments in renal insufficiency is recorded at the participant level as the proportion of timepoints where necessary dose adjustments were made appropriately in response to digoxin levels. Renal insufficiency was defined as a creatinine rise ≥ 0.3 mg/dL over 48 hours or ≥ 20% from baseline or requiring renal replacement therapy. It is reported as the mean and standard deviation of the proportion of timepoints.
Time frame: From Day 0 to Day 28 or until discharge, whichever sooner
Mortality at 7, 14, 28, 90 Days. All Cause Mortality of Patients Enrolled in the Trial.
The mortality rates at different time points
Time frame: Day 7, Day 14, Day 28, and Day 90
Development of Arrhythmia
It refers to any type of arrhythmia which represents a change from baseline. It is reported as the proportion of individuals who developed an arrhythmia.
Time frame: From Day 0 to Day 28 or until discharge, whichever sooner
Recruitment
Ability to recruit 4 patients per month to reach anticipated enrollment of 60. Data presented here is the number participants enrolled.
Time frame: up to 90 days
Organ Dysfunction (Liver - Lille Score)
Changes in liver-related function will be determined through assessment of Lille score. The model is based on: Age, Albumin, Bilirubin (initial), Bilirubin (day 7), Creatinine, PT. Survival probability at 6 months is defined by a cutoff of 0.45: 6-month survival probability of patients with a Lille model above 0.45 is about 25% contrary to patients with a Lille model below this cutoff (85% survival).
Time frame: Up to 28 days
Organ Dysfunction (Liver) With Model for End-stage Liver Disease (MELD)
Changes in liver-related function will be determined through assessment of Model for End-stage Liver Disease (MELD) score, a number that ranges from 6 (least sick) to 40 (most sick) based on blood tests. The lab tests used to determine the MELD score are creatinine, bilirubin, sodium and international normalized ratio (INR).
Time frame: Up to 28 days
Organ Dysfunction (Liver Enzyme: Bilirubin)
Changes in liver-related function will be determined through assessment of the liver enzyme bilirubin
Time frame: Up to 28 days
Organ Dysfunction (Liver Enzyme: Alkaline Phosphatase [ALP])
Changes in liver-related function will be determined through assessment of liver enzymes (alkaline phosphatase \[ALP\])
Time frame: Up to 28 days
Organ Dysfunction (Liver Enzyme: Aspartate Aminotransferase [AST])
Changes in liver-related function will be determined through assessment of liver enzymes (aspartate aminotransferase \[AST\])
Time frame: Up to 28 days
Organ Dysfunction (Liver Enzyme: Alanine Aminotransferase [ALT])
Changes in liver-related function will be determined through assessment of liver enzymes (alanine aminotransferase \[ALT\])
Time frame: Up to 28 days
Organ Dysfunction (Multi-Organ) With Sequential Organ Failure Assessment (SOFA)
Dysfunction in other organs will be assessed using Sequential Organ Failure Assessment (SOFA) score which is calculated based on a person's liver function, kidney function, nervous system, coagulation, circulation, and respiratory status. The score ranges from 0 (least sick) to 24 (most sick).
Time frame: Up to 28 days
Organ Dysfunction (Multi-Organ) With the Multi-Organ Dysfunction Score (MODS)
Dysfunction in other organs will be assessed using Multi-organ dysfunction score (MODS), calculated based on a person's liver function, kidney function, nervous system, coagulation, circulation, and respiratory status. The score ranges from 0 (least sick) to 24 (most sick).
Time frame: Up to 28 days
Development of New or Recurrent Renal Failure.
Creatinine rise ≥ 0.5 mg/dL or ≥ 20% from baseline or requiring renal replacement therapy.
Time frame: Up to 28 days
Racial and Ethnic Diversity in Subject Recruitment and Retention.
Race and ethnicity of enrolled subjects and subjects who completed the study will be summarized using count and proportion to assess the study's objective of enrolling and retaining at least 10% Black and at least 10% Hispanic participants to study completion (90-days follow-up)follow-up.
Time frame: Up to 90 days
| Milestone | Arm A: Digoxin | Arm B: No Digoxin |
|---|---|---|
| Started | 13 | 10 |
| Completed | 8 | 7 |
| Not completed | 5 | 3 |
Change in IL-6, IL-10 and TNF-alpha levels (pg/ml) at day 3 in participants with acute alcohol associated hepatitis treated with digoxin vs no digoxin.
| pg/ml | Arm A: Digoxin | Arm B: No Digoxin |
|---|---|---|
| IL-6 | -255.75 ± 44.66 | 47.16 ± 38.40 |
| IL-10 | 19.71 ± 4.28 | -7.42 ± 3.74 |
| TNF-alpha | -146.13 ± 25.43 | 26.83 ± 21.88 |
Practicality of daily digoxin measurements is recorded at the participant level as the proportion of timepoints where serum digoxin levels are checked within the pre-specified time window. It is summarized and reported as the mean and standard deviation of the proportion of eligible timepoints.
| Proportion of timepoints | Arm A: Digoxin | Arm B: No Digoxin |
|---|---|---|
| Practicality of Daily Digoxin Measurements | 1 ± 0 | — |
Feasibility of digoxin dosing is recorded at the participant level as the proportion of eligible timepoints where the scheduled digoxin dose was given. It is summarized and reported as the mean and standard deviation of the proportion of scheduled timepoints.
| Proportion of timepoints | Arm A: Digoxin | Arm B: No Digoxin |
|---|---|---|
| Feasibility of Digoxin Dosing in a Timely Manner. | 0.92 ± 0.18 | — |
Feasibility of digoxin dose adjustments in renal insufficiency is recorded at the participant level as the proportion of timepoints where necessary dose adjustments were made appropriately in response to digoxin levels. Renal insufficiency was defined as a creatinine rise ≥ 0.3 mg/dL over 48 hours or ≥ 20% from baseline or requiring renal replacement therapy. It is reported as the mean and standard deviation of the proportion of timepoints.
| Proportion of timepoints | Arm A: Digoxin | Arm B: No Digoxin |
|---|---|---|
| Feasibility of Digoxin Dose Adjustments in Renal Insufficiency. | 1 ± 0 | — |
The mortality rates at different time points
| Participants | Arm A: Digoxin | Arm B: No Digoxin |
|---|---|---|
| Day 7 | 1 | 0 |
| Day 14 | 1 | 0 |
| Day 28 | 1 | 0 |
| Day 90 | 1 | 2 |
It refers to any type of arrhythmia which represents a change from baseline. It is reported as the proportion of individuals who developed an arrhythmia.
| Participants | Arm A: Digoxin | Arm B: No Digoxin |
|---|---|---|
| Development of Arrhythmia | 2 | 1 |
Ability to recruit 4 patients per month to reach anticipated enrollment of 60. Data presented here is the number participants enrolled.
| Participants | Arm A: Digoxin | Arm B: No Digoxin |
|---|---|---|
| Recruitment | 13 | 10 |
Changes in liver-related function will be determined through assessment of Lille score. The model is based on: Age, Albumin, Bilirubin (initial), Bilirubin (day 7), Creatinine, PT. Survival probability at 6 months is defined by a cutoff of 0.45: 6-month survival probability of patients with a Lille model above 0.45 is about 25% contrary to patients with a Lille model below this cutoff (85% survival).
Results for this outcome have not been posted.
Changes in liver-related function will be determined through assessment of Model for End-stage Liver Disease (MELD) score, a number that ranges from 6 (least sick) to 40 (most sick) based on blood tests. The lab tests used to determine the MELD score are creatinine, bilirubin, sodium and international normalized ratio (INR).
Results for this outcome have not been posted.
Changes in liver-related function will be determined through assessment of the liver enzyme bilirubin
Results for this outcome have not been posted.
Changes in liver-related function will be determined through assessment of liver enzymes (alkaline phosphatase \[ALP\])
Results for this outcome have not been posted.
Changes in liver-related function will be determined through assessment of liver enzymes (aspartate aminotransferase \[AST\])
Results for this outcome have not been posted.
Changes in liver-related function will be determined through assessment of liver enzymes (alanine aminotransferase \[ALT\])
Results for this outcome have not been posted.
Dysfunction in other organs will be assessed using Sequential Organ Failure Assessment (SOFA) score which is calculated based on a person's liver function, kidney function, nervous system, coagulation, circulation, and respiratory status. The score ranges from 0 (least sick) to 24 (most sick).
Results for this outcome have not been posted.
Dysfunction in other organs will be assessed using Multi-organ dysfunction score (MODS), calculated based on a person's liver function, kidney function, nervous system, coagulation, circulation, and respiratory status. The score ranges from 0 (least sick) to 24 (most sick).
Results for this outcome have not been posted.
Creatinine rise ≥ 0.5 mg/dL or ≥ 20% from baseline or requiring renal replacement therapy.
Results for this outcome have not been posted.
Race and ethnicity of enrolled subjects and subjects who completed the study will be summarized using count and proportion to assess the study's objective of enrolling and retaining at least 10% Black and at least 10% Hispanic participants to study completion (90-days follow-up)follow-up.
Results for this outcome have not been posted.
Collected over 90 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Digoxin | 1/13 (7.7%) | 1/13 (7.7%) | 8/13 (61.5%) |
| Arm B: No Digoxin | 2/10 (20%) | 4/10 (40%) | 8/10 (80%) |
| Event | Arm A: Digoxin | Arm B: No Digoxin |
|---|---|---|
| Liver failureHepatobiliary disorders | 0/13 | 1/10 |
| Acute kidney injuryRenal and urinary disorders | 0/13 | 1/10 |
| Hepatorenal syndromeRenal and urinary disorders | 0/13 | 1/10 |
| HypotensionVascular disorders | 0/13 | 1/10 |
| Confusion ParanoiaPsychiatric disorders | 0/13 | 1/10 |
| Aspiration pneumoniaRespiratory, thoracic and mediastinal disorders | 1/13 | 0/10 |
| Event | Arm A: Digoxin | Arm B: No Digoxin |
|---|---|---|
| Abdominal painGastrointestinal disorders | 2/13 | 2/10 |
| Urinary tract infectionInfections and infestations | 0/13 | 2/10 |
| Acute kidney injuryRenal and urinary disorders | 1/13 | 2/10 |
| DiarrheaGastrointestinal disorders | 0/13 | 1/10 |
| Liver failureGastrointestinal disorders | 0/13 | 1/10 |
| VomitingGastrointestinal disorders | 0/13 | 1/10 |
| FatigueGeneral disorders | 0/13 | 1/10 |
| BacteremiaInfections and infestations | 0/13 | 1/10 |
| Upper respiratory infectionInfections and infestations | 1/13 | 1/10 |
| FallInjury, poisoning and procedural complications | 0/13 | 1/10 |
| Age, Continuous(years) | Arm A: Digoxin | Arm B: No Digoxin | Total |
|---|---|---|---|
| Mean | 46 ± 11 | 46 ± 7 | 46 ± 9 |
| Sex: Female, Male(Participants) | Arm A: Digoxin | Arm B: No Digoxin | Total |
|---|---|---|---|
| Female | 4 | 6 | 10 |
| Male | 9 | 4 | 13 |
| Race (NIH/OMB)(Participants) | Arm A: Digoxin | Arm B: No Digoxin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 9 | 8 | 17 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 1 | 5 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Digoxin | Arm B: No Digoxin | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 0 | 4 |
| Not Hispanic or Latino | 9 | 10 | 19 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Arm A: Digoxin | Arm B: No Digoxin | Total |
|---|---|---|---|
| United States | 13 | 10 | 23 |
| Model for End-Stage Liver Disease (MELD) score(score on a scale) | Arm A: Digoxin | Arm B: No Digoxin | Total |
|---|---|---|---|
| Mean | 26.7 ± 2.9 | 26.4 ± 3.4 | 26.6 ± 3.0 |
| Maddrey's Discriminant Fraction (MDF) score(score on a scale) | Arm A: Digoxin | Arm B: No Digoxin | Total |
|---|---|---|---|
| Mean | 57 ± 18 | 54 ± 19 | 55 ± 18 |
| Mean concentration Alanine aminotransferase, units/liter (U/L)(U/L) | Arm A: Digoxin | Arm B: No Digoxin | Total |
|---|---|---|---|
| Mean | 50 ± 28 | 57 ± 24 | 53 ± 26 |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2021 to primary completion in Jun 2025, 44 months.
Results were first posted in Sep 2026, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Digoxin
Chemical and Drug Induced Liver Injury →